Scott M Damrauer
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Polygenic scores (PGS) have emerged as an important tool for genetic risk prediction in medicine to identify individuals at high-risk for disease. A major limitation in their implementation is the apparent disagreement among scores for the same individual decreasing their interpretability and utility in clinical settings. Here we show that the poor agreement across PGSes for type 2 diabetes (T2D) is fully explained by statistical uncertainty in PGS-based prediction; individual-level uncertainty estimates from a single PGS explain the variability across existing PGSes. We provide an approach for the selection of high-risk individuals that incorporates measures of uncertainty and show that individuals with high confidence based on their PGS uncertainty have higher risk agreement across existing PGS and are more likely to develop T2D than high-risk individuals based on only point estimates of PGS. Together, these findings shed light on the factors underlying a roadblock in PGS implementation and underscore the need to incorporate uncertainty in PGS-based predictions.
Year:
2026
Background The comparative roles of triglyceride-rich lipoproteins (TRLs) and low-density lipoproteins (LDLs) in abdominal aortic aneurysm (AAA) pathogenesis are unclear. Objectives To evaluate the causal role of TRLs in AAA, quantify the relative effect on AAA risk (aneurysmogenicity) of TRL vs LDL particles, and prioritize lipid-lowering drug targets for AAA prevention and treatment. Methods We performed summary-level and individual-level Mendelian randomization (MR) analyses. Genetic variants were selected from 383,983 UK Biobank participants and ranked into 10 sets of variants where set 1 predominantly affected LDL cholesterol (LDL-C) and set 10 predominantly affected TRL cholesterol (TRL-C; and with mixed effects for intermediate variant sets). AAA outcome data were obtained from AAAgen (37,214 cases), FinnGen (4,439 cases), and the VA Million Veteran Program (MVP; 23,848 cases). Multivariable MR was used to assess the independent roles of LDL-C and TRL-C in AAA. For each set of variants, MR or logistic regression was used to estimate AAA odds ratios (ORs) per 10 mg/dL higher apolipoprotein B (apoB). Interaction analyses were conducted between a statin-like LDL-C-lowering variant set (set 3) and a TRL-C-lowering variant set (set 10). Drug-target MR was performed to evaluate lipid-lowering targets relevant to LDL-C- and TRL-C-lowering. Results Genetically predicted LDL-C and TRL-C concentrations were each associated independently with genetic liability for AAA after mutual adjustment, with around 3.0 to 5.5 times stronger associations for TRL-C compared to LDL-C on a per-cholesterol basis. In AAAgen, the AAA OR per 10 mg/dL increased apoB concentrations were 1.10 (95% CI, 1.05-1.14) for variant set 1 (LDL-C-predominant) and 1.89 (95% CI, 1.69-2.11) for variant set 10 (TRL-C-predominant). Using the ratio of log(OR) per 10 mg/dL apoB for set 10 versus set 1 as a conservative estimate of relative aneurysmogenicity, TRLs were approximately 3.2 to 6.9 times more aneurysmogenic than LDLs across the three studies. No evidence of interaction was observed between LDLs and TRLs, indicating additive contribution to AAA risk. Drug-target MR supported strong protective associations for genetically proxied inhibition of TRL-pathway targets, particularly APOC3 and LPL, with AAA risk. Conclusions TRLs are at least threefold more aneurysmogenic than LDLs on a per-particle basis. Therapeutic strategies targeting TRL-C especially via APOC3 and LPL-should be prioritized for AAA prevention and treatment.
Year:
2026
Purpose Portal hypertension, a major complication of chronic liver disease, leads to significant morbidity and mortality. While portal vein diameter measured on imaging has long been proposed as a non-invasive marker of portal hypertension, normative CT-based reference values and population-level associations remain incompletely characterized. Here, we aim to define contemporary reference values for portal vein diameter on clinically obtained CT and evaluate its associations with demographic, clinical, and imaging factors, as well as its diagnostic performance for portal hypertension. Methods We conducted a retrospective analysis of 20,225 clinically obtained CT scans at a single academic medical center. The main portal vein was automatically segmented using Total Segmentator, and maximum diameter extracted using the Vascular Modeling Toolkit. Associations with demographic and imaging factors were evaluated using linear mixed-effects models; prevalent liver disease and portal hypertension using logistic regression; risk of incident ascites and esophageal varices among participants with liver disease using Cox regression; and invasive hepatic venous pressures using correlation analysis and linear regression. Results The mean portal vein diameter was 12.4 mm (95% CI, 12.37–12.45). Larger diameter was independently associated with male sex (+1.4 mm), higher BMI (+0.11 mm/kg/m 2 ), greater height (+0.04 mm/cm), and older age (+0.05 mm/10 years) (all p < 0.001), and was substantially larger on contrast-enhanced abdomen/pelvis CT (+2.4 mm, p < 0.001). Each 1-mm increase in portal vein diameter was associated with higher odds of prevalent liver disease (OR 1.06; 95% CI, 1.04–1.08) and portal hypertension (OR 1.18; 95% CI, 1.12–1.28). Among individuals with liver disease, greater diameter predicted higher risk of incident esophageal varices (baseline diameter HR 1.50; 95% CI, 1.14–2.08) and ascites (HR per mm increase in diameter 1.06; 95% CI, 1.003–1.12). However, portal vein diameter demonstrated weak to no association with invasively measured hepatic venous pressures. Conclusion In this large, EHR-linked imaging cohort, the mean portal vein diameter on CT was 12.4 mm and varied with demographic and imaging factors. Larger diameter was associated with liver disease, portal hypertension, and subsequent development of varices and ascites, supporting use of portal vein diameter as a pragmatic screening or enrichment tool within multimodal clinical frameworks. Key Results Mean portal vein diameter on routine clinical CT was 12.4 mm (95% CI, 12.37–12.45) and varied with sex, height, BMI, exam type, contrast use, and clinical setting. Each 1-mm increase in portal vein diameter was associated with higher odds of prevalent liver disease (OR 1.06) and portal hypertension (OR 1.18). Among individuals with liver disease, larger portal vein diameter predicted higher risk of incident esophageal varices and ascites, independent of demographic and imaging factors.
Year:
2026
Background Epigenetic mechanism underlying susceptibility to abdominal aortic aneurysm (AAA) remain poorly understood. Identifying causal DNA methylation markers for AAA can elucidate the regulatory processes that drive aneurysm formation and would accelerate translational applications. We leveraged the VA Million Veteran Program (MVP) to identify methylation biomarkers and delineate underlying pathways. Methods We first conducted an epigenome-wide association study (EWAS) of incident AAA (1,324 cases; 42,065 non-cases), performed stratified analyses by population group and smoking status, and conducted Mendelian randomization (MR) to facilitate casual inference of the CpG-AAA association. Chromatin state, island context, and TF binding were implicated through functional annotation of identified CpGs. To identify genes impacted by change in methylation state, we aligned associations with transcriptional data obtained in blood, aorta, and liver. We performed expression quantitative trait methylation (eQTM) to capture CpG–gene-expression links across the genome. Network MR was used to test cardiometabolic mediation. Finally, we developed a risk predictor using methylation data using a penalized regression model, evaluating its performance against a comprehensive clinical model. Results EWAS identified 1,253 CpGs associated with incident AAA, and MR supported a putative causal role for 151 of these associations. Functional annotation pointed to predominantly distal, enhancer-centered regulation and enrichment of inflammatory transcription factor programs (e.g., AP-1). This distal architecture was consistent with eQTM results, which showed a larger number of trans associations. Network MR identified 231 putative mediation pathways linking CpGs to AAA, including 179 via cardiometabolic traits and 52 via immune/inflammation-related traits. Among cardiometabolic mediators, blood lipids accounted for >40% of mediation effect linking LDLR-associated CpGs to AAA risk. Among immune/inflammation-related mediators, platelet count and circulating proteins including NEXN, IL1RN, ADH1B, and MMP12 emerged as key intermediates. Genetic colocalization highlighted an aorta-specific cg17511968–WNT6–AAA axis, and network MR implicated IL1RN and MMP12 as downstream protein mediators of association between WNT6-proximal CpGs and AAA. Finally, a methylation risk score improved discrimination when added to a clinical model (AUC 0.775; 95% CI, 0.749–0.801) for incident AAA prediction. Conclusions This study identified putative causal DNA methylation markers for AAA, and multi-omics analyses implicate AP-1–linked inflammatory transcriptional programs, blood lipids, platelet count, and multiple immune/inflammation-related proteins as key pathways underlying methylation-associated AAA risk.
Year:
2026
Stroke remains a leading cause of death and disability worldwide. Current antiplatelet and anticoagulant treatments are prone to failure. Heritable blood and platelet traits contribute to stroke risk, but related mechanisms are not fully understood. Platelets bind to damaged endothelial walls to initiate thrombosis, but erythrocyte and leukocyte recruitment are involved in stroke pathogenesis. We aimed to identify causal blood-related cells and mechanisms that modulate stroke risk. By two sample Mendelian Randomization (MR), increased platelet count heightened stroke risk (Odds ratio [OR] 1.03 per 1 SD unit increase in platelet count, P=1×10 -2 ). However, these effects were relatively weak and complicated by similar effects from erythrocyte and leukocyte traits. To ascertain key blood traits that influence stroke, we applied Bayesian Model Averaging (MR-BMA) and identified platelet count and mean platelet volume as key positive regulators for stroke risk. We validated an epidemiologic association between increased platelet count and higher stroke risk among a large patient cohort. Taken together, these findings indicate that platelet traits are the most critical risk factors for stroke, among analyzed blood cell traits. To deconvolute multiple underlying genetic mechanisms by which platelet traits impact stroke risk, we clustered platelet count variants using noise-augmented directional clustering (NAvMix). We identified 13 clusters, two of which were highly predictive for increased stroke risk (OR 1.31 per SD unit increase in platelet count, P<1×10 -6 ). Pathway analyses on eQTLs linked to variants in these subclusters indicated enrichment for endothelial cell adhesion or platelet reactivity. Colocalization analysis of stroke and platelet count loci identified genes implicated in platelet reactivity ( RIN3 ) and peroxisome biogenesis ( PEX6/PEX29 ). These findings reflect complex mechanisms underlying platelet trait variation and reveal key pathways that influence stroke risk through multiple cell types and biological mechanisms, including platelet biology and endothelial cell adhesion. An approach combining novel MR methods with subclustering may be a viable method to ascertain causal mechanisms related to other closely related exposure traits.
Year:
2025
Plasma proteins capture dynamic physiological processes and may offer more immediate insight into disease risk than static genetic predictors. We evaluated the predictive utility of proteomic risk scores (ProRS) versus polygenic risk scores (PRS) across 301 phenotypes in 39,843 participants from the UK Biobank Pharma Proteomics Project. ProRS, trained on prevalent cases, were tested for incident disease and benchmarked against PRS derived from genome-wide association statistics. Among 268 phenotypes with informative signals, ProRS outperformed PRS in 88% of traits (a median C-index improvement of 9.6%), showing strongest gains for circulatory, metabolic, and immune conditions. Combined models further improved prediction, particularly for traits with higher heritability. Longitudinal analyses showed that ProRS values were elevated years before diagnosis. External validation in 841 Penn Medicine BioBank participants confirmed consistent performance and transferability, with AUC improvements up to 4.18% over PRS alone. Plasma proteomic profiling provides complementary, temporally responsive information that enhances individual-level disease prediction.
Year:
2025
Background Bicuspid aortic valve (BAV) is the most common congenital heart defect but often evades timely diagnosis due to variable clinical presentations. Prior to October 2024, no specific diagnosis code existed for BAV, limiting retrospective identification. Objectives To develop and validate a natural language processing (NLP) system for automated extraction of heart valve morphology from echocardiographic reports, with focus on BAV detection. Methods We developed a rule-based NLP system using MedSpaCy to analyze echocardiographic reports from the Veterans Affairs Corporate Data Warehouse. The system was trained on 555 manually annotated reports and validated on 170 held-out reports. Performance was measured using precision, recall, and F1-score for valve leaflet structure identification. Results The NLP system achieved excellent performance for BAV detection with precision of 0.984, recall of 0.955, and F1-score of 0.969. When applied to 14,453,591 echocardiographic documents from 3,478,658 patients, the system identified 84,019 patients (2.42%) with affirmed BAV. Among patients identified by the ICD-10 code Q23.81, NLP showed 86.1% concordance, with manual review confirming NLP accuracy in discordant cases. Conclusions This NLP approach enables large-scale retrospective identification of BAV patients from clinical text, creating the largest BAV cohort to date and facilitating future cardiovascular research and clinical decision-making.
Year:
2025
Importance Polygenic background modifies variant penetrance in hypertrophic (HCM) and dilated (DCM) cardiomyopathy, diseases with opposing morphologic characteristics and inversely related genetic pathways. Whether polygenic susceptibility for one disease protects against monogenic risk for the other remains unexplored. Objective To characterize if polygenic background bidirectionally modifies pathogenicity of established rare variants associated with HCM and DCM. Design Cross-sectional study. Setting The Penn Medicine BioBank (PMBB). Participants Volunteers enrolled in PMBB with available electronic health record and genotyping data. Exposures Normalized polygenic scores (PGS) for HCM and DCM, as well as carrier status of pathogenic variants in established HCM or DCM genes. Main Outcomes HCM and DCM defined using electronic health record diagnosis and procedure code, as well as echocardiogram measurements derived from medical records. Results This study included 49,434 PMBB participants. An increased HCM PGS was associated with significantly increased left ventricular ejection fraction (LVEF), decreased left ventricular internal diameter at end-diastole (LVIDd), and increased interventricular septal thickness (IVS) (p 95% probability of difference in AUROC). Conclusions and Relevance HCM and DCM risk are markedly modified by polygenic background which exists on an overlapping spectrum. Consideration of polygenic background may offer clinical value through improving understanding and prediction of these inherited cardiomyopathies. Key Points Question How is risk for hypertrophic and dilated cardiomyopathy modified by polygenic background? Findings Polygenic scores for HCM and DCM associate with clinical and echocardiographic measures relevant to both diseases and inversely modify the penetrance of pathogenic variants. Meaning Polygenic background contributes to HCM and DCM susceptibility, and exists on an overlapping spectrum.
Year:
2025
Background Thoracic aortic aneurysm and dissection (TAAD) can have catastrophic health consequences. Eleven genes have strong or definitive evidence for causing heritable TAAD (HTAAD). However, patients are seldom tested for rare pathogenic (P) or likely pathogenic (LP) variants in these HTAAD genes absent a strong family history or syndromic features, and little is known about either their prevalence in the general population or the associated TAAD risk. Furthermore, the degree to which common genetic variation associated with TAAD modifies rare variant pathogenicity is unknown. Methods Penn Medicine Biobank (PMBB) and MyCode participants volunteered to have electronic health records linked to biospecimen data including DNA which has undergone genome-wide genotyping and whole exome sequencing. P/LP HTAAD gene variants were adjudicated according to American College of Medical Genetics and Genomics standards, and logistic regression was performed to determine the associated risk of prevalent TAAD. An ascending aortic diameter (AscAoD) polygenic risk score (PRS) was derived from a genome-wide association study (GWAS) of aortic diameter to assess common variant TAAD risk, and regression analyses were performed to determine the modifying effect this PRS had on penetrance of rare variants. Results Across the two analytic cohorts, 0.2-0.3% of participants carried a P/LP HTAAD gene variant. Compared to individuals without a P/LP variant, carrying a P/LP HTAAD variant was associated with a 13.5-fold increased risk of a diagnosis of TAAD (95% confidence interval [CI] 5.3 to 34.6, P <0.001) with variable effects when stratified by gene. A one standard deviation increase in the AscAoD PRS was associated with a 1.43-fold increased risk of TAAD (95% CI 1.39 to 1.47, P <0.001). TAAD prevalence was higher among individuals carrying a P/LP HTAAD gene variant in the highest PRS quintile compared to carriers in the lowest PRS quintile (relative risk = 2.32, 95% CI 1.29 to 4.17, P <0.01) suggesting that common variant risk may be an important modifier of rare variant risk for TAAD. Conclusions Our results indicate that P/LP HTAAD gene variants confer a significant increased risk of TAAD in the population at-large, and that polygenic risk may be an important modifier of rare variant risk.
Year:
2025
Background Atherosclerosis and arteriosclerosis are major contributors to cardiovascular disease (CVD), yet their shared and distinct molecular underpinnings remain incompletely understood. This study integrates proteomics, Bayesian colocalization, and Mendelian randomization (MR), and structural modelling to explore the shared and distinct plasma proteome associated with arteriosclerosis and atherosclerosis across different vascular beds. Methods We leveraged cis -pQTLs for 5,813 unique proteins from the UK Biobank (UKB) Pharma Proteomics Project (N=54,219) and deCODE genetics (N=35,559) and assessed the association with five arteriosclerotic/atherosclerotic markers, as well as eight cardiovascular events, using Bayesian colocalization and bidirectional MR. We validated the findings through tissue-specific transcriptomics, observational data from UKB, and AlphaFold3 for structural prediction. Finally, mediation analysis evaluated the role of vascular traits in linking proteins to CVD risk. Results We prioritized ten proteins potentially causally associated with both the arteriosclerotic/atherosclerotic markers and cardiovascular events. Five of them (ANGPTL4, APOB, BRAP, LPA, and ZPR1), were associated with increased levels of arteriosclerosis/ atherosclerosis and risk of CVD, whereas four (DUSP13, FN1, IL6R, and MMP12) were associated with reduced levels of arteriosclerosis/ atherosclerosis and risk of CVD. ABO was associated with increased risk of peripheral artery disease (PAD) and CVD but inversely related to ASI. Mediation analyses estimated that LPA’s effect on stroke was primarily mediated through carotid plaque (92.4%), while DUSP13’s effect on coronary artery disease was primarily mediated via PAD (91.0%). Observational analyses and transcriptomic validation corroborated these associations. Structural modelling using AlphaFold3 identified key functional variants in several proteins, including ANGPTL4 and FN1, potentially underlying the pathogenic mechanists. Conclusions The present study elucidates the shared and distinct proteomic signatures across arteriosclerosis, atherosclerosis, and cardiovascular disease, underscoring the importance of vascular-bed-specific mechanisms. These identified proteins offer promising avenues for biomarker-driven risk stratification and therapeutic interventions, with potential for dual-purpose interventions across vascular territories.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Collaborators (45)
Sharlene Day
Associate Professor
University of Pennsylvania
Daniel Rader
Chair
University of Pennsylvania
Anurag Verma
Assistant Professor
University of Pennsylvania
Walter R. Witschey
Associate Professor
University of Pennsylvania
Katherine Liao
Associate Professor
Harvard Medical School
Abbas Dehghan
Reader in cardiometabolic diseases
Imperial College London
Anjali T. Owens
Assistant Professor, Clinician-Educator
University of Pennsylvania Perelman School of Medicine
Jean-Tristan Brandenburg
Senior researcher (Cancer team)
University of Witwatersrand
Joshua Spin
Clinical Assistant Professor
Stanford University School of Medicine
Struan Grant
Professor of Genetics and Pediatrics
University of Pennsylvania
Christopher Thom
Children's Hospital of Philadelphia
Scott LeMaire
Associate Chief Scientific Officer and Associate Dean for Research
Baylor College of Medicine
Sarah Abramowitz
Stanford University
Adam Heath
The University of Texas Health Science Center at Houston School of Public Health
Sander W. van der Laan
Assistant Professor
University Medical Center Groningen
Dokyoon Kim
Assistant Professor
University of Pennsylvania
Braxton Mitchell
Professor
University of Maryland
Clint Miller
Associate Professor
Stanford University
Satoshi Koyama
Associate Member
Broad Institute
Themistocles L Assimes
Attending Cardiologist
Stanford University School of Medicine
Ravi Madduri
Senior Scientist
Argonne National Laboratory
Patricia Munroe
Professor of Molecular Medicine
Queen Mary University of London
Pradeep Natarajan
Associate Professor
Harvard Medical School
John Blangero
Professor/Director Genomics Computing Center
University of Texas Rio Grande Valley School of Medicine
Paul de Vries
Assistant Professor
The University of Texas Health Science Center at Houston School of Public Health
Marijana Vujkovic
Research Assistant Professor
University of Pennsylvania
Benjamin F. Voight
Professor
University of Pennsylvania
Paul Elliott
Professor of Epidemiology and Public Health Medicine
Imperial College London
Myriam Fornage
-
Michael Levin
Cardiologist
Corporal Michael J. Crescenz VA Medical Center
Dianna M Milewicz
The University of Texas Health Science Center at Houston
Shoa L. Clarke
Stanford University School of Medicine
Adolfo Correa
Professor
University of Mississippi Medical Center
Dongchuan Guo
Professor
The University of Texas Health Science Center at Houston School of Public Health
Nosheen Reza
University of Pennsylvania
John Carr
Professor with Tenure
Vanderbilt University Medical Center
Anne B Newman
University of Pittsburgh
Ioanna Tzoulaki
Research Director
Biomedical Research Foundation of the Academy of Athens
Jingxian Huang
Imperial College London
Jian Huang
Senior Scientist
Agency for Science, Technology and Research (A*STAR)
Rima Mustafa
University of Oxford
Shuai Yuan
Karolinska Institutet
Philip S Tsao
Stanford University
Kyong-Mi Chang
Professor of Medicine & Associate Chief of Staff for R&D
University of Pennsylvania
Maryam Kavousi
Professor of Population Cardiovascular Health
Erasmus MC
Make your next move.
Prepare your application
Review drafts before you send them.